Table 2. HR-HPV DNA, RNA and p16 positivity in HNSCC subsites by HPV status.

		All HNSCC (N = 189)	Oropharynx (N = 28)	Non-oropharynx (N = 161)
HPV type	Marker positivity	Positive N (%)	Positive N (%)	Positive N (%)
Any HR-HPV	DNA	23 (12.2)	14 (50.0)	9 (5.6)
	DNA & RNA‡	2 (1.1)	1 (3.6)	1 (0.6)
	DNA, RNA & p16‡	0 (0.0)	0 (0.0)	0 (0.0)
HPV16	DNA	20 (10.6)	12 (42.9)	8 (5.0)
	DNA & RNA	1 (0.5)	0 (0.0)	1 (0.6)
	DNA, RNA & p16	0 (0.0)	0 (0.0)	0 (0.0)
Non-HPV16 HR types	DNA	5 (2.6)	3 (10.7)1	2 (1.2)2
	DNA & RNA	1 (0.5)	1 (3.6)3	0 (0.0)
	DNA, RNA & p16	0 (0.0)	0 (0.0)	0 (0.0)

^‡HPV RNA and p16 expression was examined in all HR-HPV DNA-positive cases (n = 23) and a randomly selected subset of HR-HPV DNA-negative cases (n = 13). All HPV DNA-negative cases were RNA-negative. One case was p16-positive.

¹Coinfection, HPV16 plus HPV18 (n = 1), and single infections, HPV18 (n = 2).

²Coinfections, HPV16 plus HPV18 (n = 1), and HPV18 plus HPV39 (n = 1)

³HPV18 (n = 1)